ValueOS

← Dashboard›Dr. Fatima Al-Khalil›Guideline Adherence

Provider

Contract

Period

25Requirements

76.8%Overall Compliance

↑ 3.2ppvs Prior Period

Active Guidelines — Contract 1: Primary Care Performance

Compliance Heatmap — Click any cell to filter requirements below

≥80%

60–79%

<60%

Chapter / Section	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Ch 2: Diagnosis & Classification	92%	94%	93%	95%
Ch 4: Comprehensive Medical Eval.	71%	74%	76%	78%
Ch 6: Glycemic Targets	62%	65%	68%	72%
Ch 8: Obesity & Weight Management	48%	50%	52%	54%
Ch 9: Pharmacologic Approaches	78%	80%	82%	84%
Ch 10: CVD & Risk Management	68%	70%	73%	76%
Ch 11: Microvascular Complications	58%	60%	64%	68%

ADA Standards of Care 2024 · 25 of 25 requirements

Req. ID ↕	Ch.	Category	Requirement ↑	Grade	Compliance ↑	Eligible ↕	Compliant
ADA-2024-020	Ch 4	Testing	Hepatitis B screening before initiating certain immunosuppressive therapies	E	28.6%	42	12
ADA-2024-017	Ch 8	Referral	Referral to structured weight management program for BMI ≥30	C	32.4%	196	64
ADA-2024-024	Ch 4	Screening	Assessment for diabetes distress at routine visits using validated questionnaire	C	34.1%	340	116
ADA-2024-010	Ch 4	Referral	Pneumococcal vaccination for adults with diabetes	C	38.5%	340	131
ADA-2024-009	Ch 4	Education	Diabetes self-management education referral within first year of diagnosis	B	42.1%	340	143
ADA-2024-018	Ch 4	Monitoring	Annual thyroid function testing (TSH) for patients on insulin or with symptoms	C	44.7%	340	152
ADA-2024-025	Ch 4	Education	Medical nutrition therapy and nutrition counseling referral	B	45.9%	340	156
ADA-2024-016	Ch 8	Education	Weight management counseling and individualized goal setting	B	48.2%	280	135
ADA-2024-019	Ch 11	Referral	Podiatry referral for patients with peripheral neuropathy or prior foot ulcer	B	52.8%	89	47
ADA-2024-013	Ch 9	Treatment	Medication intensification if HbA1c above individualized target for >3 months	A	56.8%	148	84
ADA-2024-007	Ch 4	Screening	Annual screening for depression using validated tool (PHQ-9)	B	57.8%	340	197
ADA-2024-022	Ch 9	Treatment	GLP-1 RA or SGLT2i for patients with established atherosclerotic CVD or HF	A	58.4%	137	80
ADA-2024-006	Ch 11	Testing	Annual eGFR and uACR screening for diabetic kidney disease	B	62.4%	340	212
ADA-2024-008	Ch 4	Education	Smoking cessation counseling at every visit for current smokers	A	64.7%	51	33
ADA-2024-021	Ch 6	Monitoring	CGM or SMBG regimen established, reviewed, and adjusted at every visit	B	66.2%	340	225
ADA-2024-003	Ch 11	Screening	Annual comprehensive foot examination	B	68.5%	340	233
ADA-2024-002	Ch 11	Screening	Annual comprehensive dilated eye examination	B	71.2%	340	242
ADA-2024-023	Ch 10	Treatment	Aspirin therapy (75–162 mg/day) for secondary CVD prevention	A	74.8%	137	103
ADA-2024-014	Ch 10	Monitoring	Lipid profile measurement at least annually	B	76.5%	340	260
ADA-2024-004	Ch 10	Treatment	Statin therapy for patients aged ≥40 with additional CVD risk factors	A	78.9%	312	246
ADA-2024-015	Ch 10	Treatment	ACE inhibitor or ARB for patients with confirmed diabetic nephropathy	A	82.3%	96	79
ADA-2024-011	Ch 6	Monitoring	Individualized glycemic target established and documented in care plan	A	82.4%	340	280
ADA-2024-001	Ch 6	Testing	HbA1c testing at least every 6 months in patients meeting treatment goals	A	88.2%	340	300
ADA-2024-012	Ch 9	Treatment	Metformin as first-line pharmacologic therapy (absent contraindications)	A	91.2%	298	272
ADA-2024-005	Ch 4	Monitoring	Blood pressure measurement at every routine visit	A	94.1%	340	320